Do you want to read an article? Please log in or register.
Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Duvergé L, Bondiau PY, Claude L, Supiot S, Vaugier L, Thillays F, Doyen J, Ricordel C, Léna H, Bellec J, Chajon E, de Crevoisier R, Castelli J
doi: 10.1016/j.lungcan.2021.05.016
RECOMMENDED
Lung Cancer
Definitive treatment patterns and survival in stage II non-small cell lung cancer
doi: 10.1016/j.lungcan.
RECOMMENDED
Lung Cancer
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
Lancet Respir Med.
Altorki NK, Wang X, Wigle , Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman L
doi: 10.1016/S2213-2600
RECOMMENDED
Lung Cancer
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Alexander Meisel, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol.
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
doi: 10.1016/S1470-2045(19)30519-4.
RECOMMENDED
Lung CancerPleural DiseasesFurther Publications
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
Chest.
Suresh K, Naidoo J, Lin CT, Danoff S
doi: 10.1016/
Lung Cancer
Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function
Acta Oncol.
Ishihara T, Yamada K, Harada A, Yukiue H, Tanahashi M, Niwa H, Matsui T, Yokomura K, Ejima Y, Sasaki R
doi: 10.1080/0284186X.
RECOMMENDED
Lung Cancer
Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RAEM, Wouters MWJM, Marang-van de Mheen PJ, Schreurs WH, MDT study group
doi: 10.1016/j.chest.2020.07.054.
RECOMMENDED
Lung Cancer
Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T
doi: 10.1016/j.cllc.2020.05.024.
Lung Cancer
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Lancet Respir Med.
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC